Physician profile
Robert A Sullivan
NPI 1437190436
$7,020.92
in general payments reported to CMS, 2019-2025
24 companies · $1,320 in 2025
The $1,320 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,977 · 2020: $1,368 · 2021: $463 · 2022: $259 · 2023: $806 · 2024: $828 · 2025: $1,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,761 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,760.85 |
| Education | $193.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,522.47 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,413.50 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $1,003.54 | 2019-2025 | Dupixent |
| Genzyme Corporation | $719.68 | 2019-2025 | |
| Genentech USA, INC. | $565.81 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $336.89 | 2019-2025 | |
| Blueprint Medicines Corporation | $253.48 | 2023-2024 | Ayvakit |
| Pfizer INC. | $158.26 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $149.30 | 2020-2025 | Takhzyro |
| Genentech, INC. | $145.76 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $128.73 | 2019-2021 | |
| Kaleo, INC. | $125.18 | 2020-2022 | |
| Csl Behring | $114.86 | 2019-2025 | Hizentra |
| Ars Pharmaceuticals Operations, INC. | $113.61 | 2025 | Neffy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.08 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $44.73 | 2024-2025 | Orladeyo |
| Optinose US, INC. | $34.19 | 2020 | |
| Grifols USA, LLC | $30.53 | 2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $22.88 | 2025 | Ohtuvayre |
| Pharming Healthcare, INC. | $22.41 | 2019 | |
| Shire North American Group INC | $16.09 | 2019 | |
| Galderma Laboratories, L.P. | $15.47 | 2025 | Nemluvio |
| Mylan Specialty L.P. | $11.62 | 2020 | |
| Circassia INC. | $10.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.